Levonorgestrel releasing intrauterine device - ContraMed

Drug Profile

Levonorgestrel releasing intrauterine device - ContraMed

Alternative Names: LevoCept

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator ContraMed
  • Class Hormonal replacements; Norpregnanes; Oral contraceptives; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Contraception

Most Recent Events

  • 02 Dec 2016 ContraMed initiates enrolment in a phase II trial for Contraception in USA (Intrauterine)
  • 01 Nov 2016 Phase-II clinical trials in Contraception in USA (Intrauterine) (NCT02882191)
  • 03 Oct 2016 ContraMed plans a phase II trial for Contraception in USA (NCT02882191)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top